European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics – Update 2019
European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO), and the European Organization for Research and Treatment of Cancer (EORTC)
Cutaneous melanoma (CM) is potentially the most dangerous form of skin tumor and causes 90% of skin cancer mortality. A unique collaboration of multidisciplinary experts from the European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO), and the European Organization of Research and Treatment of Cancer (EORTC) was formed to make recommendations on CM diagnosis and treatment, based on systematic literature reviews and the experts' experience. The diagnosis of melanoma can be made clinically and shall always be confirmed through dermatoscopy. If a melanoma is suspected, a histopathological examination is required. Sequential digital dermatoscopy and full-body photography can be used in risk persons to detect the development of melanomas at an earlier stage. Where available, confocal reflectance microscopy can improve clinical diagnosis in special cases. Melanoma shall be classified according to the 8th version of the AJCC classification. Thin melanomas up to 0.8 mm tumor thickness does not require further imaging diagnostics. From stage IB onwards, examinations with lymph node sonography are recommended, but no further imaging examinations. From stage IIC whole-body examinations with CT or PET-CT in combination with brain MRI are recommended. From stage III and higher, mutation testing is recommended, particularly for BRAF V600 mutation. It is important to provide a structured follow-up to detect relapses and secondary primary melanomas as early as possible. There is no evidence to support the frequency and extent of examinations. A stage-based follow-up scheme is proposed, which, according to the experience of the guideline group, covers the minimum requirements; further studies may be considered. This guideline is valid until the end of 2021.
Gepubliceerd - feb. 2020
Duik in de onderzoeksthema's van 'European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics – Update 2019'. Samen vormen ze een unieke vingerafdruk.
Melanoma Medicijnen en Levenswetenschappen 100%
Guidelines Medicijnen en Levenswetenschappen 77%
Dermoscopy Medicijnen en Levenswetenschappen 41%
Skin Medicijnen en Levenswetenschappen 24%
Photography Medicijnen en Levenswetenschappen 17%
Positron Emission Tomography Computed Tomography Medicijnen en Levenswetenschappen 16%
Skin Neoplasms Medicijnen en Levenswetenschappen 15%
European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO), and the European Organization for Research and Treatment of Cancer (EORTC) (2020). European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics – Update 2019. European Journal of Cancer, 126, 141-158. https://doi.org/10.1016/j.ejca.2019.11.014
European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO), and the European Organization for Research and Treatment of Cancer (EORTC). / European consensus-based interdisciplinary guideline for melanoma. Part 1 : Diagnostics – Update 2019. In: European Journal of Cancer. 2020 ; Vol. 126. blz. 141-158.
@article{427cf789c67f469eac52ee99e87434fc,
title = "European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics – Update 2019",
abstract = "Cutaneous melanoma (CM) is potentially the most dangerous form of skin tumor and causes 90% of skin cancer mortality. A unique collaboration of multidisciplinary experts from the European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO), and the European Organization of Research and Treatment of Cancer (EORTC) was formed to make recommendations on CM diagnosis and treatment, based on systematic literature reviews and the experts' experience. The diagnosis of melanoma can be made clinically and shall always be confirmed through dermatoscopy. If a melanoma is suspected, a histopathological examination is required. Sequential digital dermatoscopy and full-body photography can be used in risk persons to detect the development of melanomas at an earlier stage. Where available, confocal reflectance microscopy can improve clinical diagnosis in special cases. Melanoma shall be classified according to the 8th version of the AJCC classification. Thin melanomas up to 0.8 mm tumor thickness does not require further imaging diagnostics. From stage IB onwards, examinations with lymph node sonography are recommended, but no further imaging examinations. From stage IIC whole-body examinations with CT or PET-CT in combination with brain MRI are recommended. From stage III and higher, mutation testing is recommended, particularly for BRAF V600 mutation. It is important to provide a structured follow-up to detect relapses and secondary primary melanomas as early as possible. There is no evidence to support the frequency and extent of examinations. A stage-based follow-up scheme is proposed, which, according to the experience of the guideline group, covers the minimum requirements; further studies may be considered. This guideline is valid until the end of 2021.",
keywords = "AJCC classification, Confocal reflectance microscopy, Cutaneous melanoma, Dermatoscopy, Follow-up examinations, Imaging diagnostics, Mutation testing, Primary diagnosis, Sequential digital dermatoscopy, Total body photography",
author = "{European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO), and the European Organization for Research and Treatment of Cancer (EORTC)} and Claus Garbe and Teresa Amaral and Ketty Peris and Axel Hauschild and Petr Arenberger and Lars Bastholt and Veronique Bataille and {del Marmol}, Veronique and Brigitte Dr{\'e}no and Fargnoli, {Maria Concetta} and Grob, {Jean Jacques} and Christoph H{\"o}ller and Roland Kaufmann and Aimilios Lallas and Celeste Lebb{\'e} and Josep Malvehy and Mark Middleton and David Moreno-Ramirez and Giovanni Pellacani and Philippe Saiag and Stratigos, {Alexander J.} and Ricardo Vieira and Iris Zalaudek and Eggermont, {Alexander M.M.}",
note = "Publisher Copyright: {\textcopyright} 2019",
European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO), and the European Organization for Research and Treatment of Cancer (EORTC) 2020, 'European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics – Update 2019', European Journal of Cancer, vol. 126, blz. 141-158. https://doi.org/10.1016/j.ejca.2019.11.014
European consensus-based interdisciplinary guideline for melanoma. Part 1 : Diagnostics – Update 2019. / European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO), and the European Organization for Research and Treatment of Cancer (EORTC).
In: European Journal of Cancer, Vol. 126, 02.2020, blz. 141-158.
T1 - European consensus-based interdisciplinary guideline for melanoma. Part 1
T2 - Diagnostics – Update 2019
AU - European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO), and the European Organization for Research and Treatment of Cancer (EORTC)
AU - Garbe, Claus
AU - Amaral, Teresa
AU - Peris, Ketty
AU - Hauschild, Axel
AU - Arenberger, Petr
AU - Bastholt, Lars
AU - Bataille, Veronique
AU - del Marmol, Veronique
AU - Dréno, Brigitte
AU - Fargnoli, Maria Concetta
AU - Grob, Jean Jacques
AU - Höller, Christoph
AU - Kaufmann, Roland
AU - Lallas, Aimilios
AU - Lebbé, Celeste
AU - Malvehy, Josep
AU - Middleton, Mark
AU - Moreno-Ramirez, David
AU - Pellacani, Giovanni
AU - Saiag, Philippe
AU - Stratigos, Alexander J.
AU - Vieira, Ricardo
AU - Zalaudek, Iris
AU - Eggermont, Alexander M.M.
N1 - Publisher Copyright: © 2019
N2 - Cutaneous melanoma (CM) is potentially the most dangerous form of skin tumor and causes 90% of skin cancer mortality. A unique collaboration of multidisciplinary experts from the European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO), and the European Organization of Research and Treatment of Cancer (EORTC) was formed to make recommendations on CM diagnosis and treatment, based on systematic literature reviews and the experts' experience. The diagnosis of melanoma can be made clinically and shall always be confirmed through dermatoscopy. If a melanoma is suspected, a histopathological examination is required. Sequential digital dermatoscopy and full-body photography can be used in risk persons to detect the development of melanomas at an earlier stage. Where available, confocal reflectance microscopy can improve clinical diagnosis in special cases. Melanoma shall be classified according to the 8th version of the AJCC classification. Thin melanomas up to 0.8 mm tumor thickness does not require further imaging diagnostics. From stage IB onwards, examinations with lymph node sonography are recommended, but no further imaging examinations. From stage IIC whole-body examinations with CT or PET-CT in combination with brain MRI are recommended. From stage III and higher, mutation testing is recommended, particularly for BRAF V600 mutation. It is important to provide a structured follow-up to detect relapses and secondary primary melanomas as early as possible. There is no evidence to support the frequency and extent of examinations. A stage-based follow-up scheme is proposed, which, according to the experience of the guideline group, covers the minimum requirements; further studies may be considered. This guideline is valid until the end of 2021.
AB - Cutaneous melanoma (CM) is potentially the most dangerous form of skin tumor and causes 90% of skin cancer mortality. A unique collaboration of multidisciplinary experts from the European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO), and the European Organization of Research and Treatment of Cancer (EORTC) was formed to make recommendations on CM diagnosis and treatment, based on systematic literature reviews and the experts' experience. The diagnosis of melanoma can be made clinically and shall always be confirmed through dermatoscopy. If a melanoma is suspected, a histopathological examination is required. Sequential digital dermatoscopy and full-body photography can be used in risk persons to detect the development of melanomas at an earlier stage. Where available, confocal reflectance microscopy can improve clinical diagnosis in special cases. Melanoma shall be classified according to the 8th version of the AJCC classification. Thin melanomas up to 0.8 mm tumor thickness does not require further imaging diagnostics. From stage IB onwards, examinations with lymph node sonography are recommended, but no further imaging examinations. From stage IIC whole-body examinations with CT or PET-CT in combination with brain MRI are recommended. From stage III and higher, mutation testing is recommended, particularly for BRAF V600 mutation. It is important to provide a structured follow-up to detect relapses and secondary primary melanomas as early as possible. There is no evidence to support the frequency and extent of examinations. A stage-based follow-up scheme is proposed, which, according to the experience of the guideline group, covers the minimum requirements; further studies may be considered. This guideline is valid until the end of 2021.
KW - AJCC classification
KW - Confocal reflectance microscopy
KW - Cutaneous melanoma
KW - Dermatoscopy
KW - Follow-up examinations
KW - Imaging diagnostics
KW - Mutation testing
KW - Primary diagnosis
KW - Sequential digital dermatoscopy
KW - Total body photography
European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO), and the European Organization for Research and Treatment of Cancer (EORTC). European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics – Update 2019. European Journal of Cancer. 2020 feb.;126:141-158. doi: 10.1016/j.ejca.2019.11.014